Xcout Intel
BlossomHill Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to BlossomHill Therapeutics, Inc. among biotech companies — ranked by similarity to what BlossomHill Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see BlossomHill Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BlossomHill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
BlossomHill Therapeutics, Inc. at a glance
BlossomHill Therapeutics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (BLSM) with a market capitalisation of $572.6M. Xcout tracks 35 named people at BlossomHill Therapeutics, Inc., including Jingrong Jean Cui (President and Chief Executive Officer).
BlossomHill Therapeutics, Inc. leadership
- Jingrong Jean CuiPresident and Chief Executive Officer
- Jason A KeyesCFO & Executive VP
- Jason KeyesExecutive Vice President and Chief Financial Officer
- Geoff OxnardChief Medical Officer & Executive VP
- Geoff Oxnard, M.D.Executive Vice President and Chief Medical Officer
- Vincent Liptak, J.D., Ph.D., MBAExecutive Vice President and General Counsel
29 more named people on record for BlossomHill Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Recent BlossomHill Therapeutics, Inc. news
- IPOBlossomHill Therapeutics, Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
- IPOIPO registration (S-1)
5 corporate events on record, with sources — see the full timeline →
Top 12 BlossomHill Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to BlossomHill Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Biotechnology
Breakthru Medicine is a privately held biotechnology company headquartered in Phoenix, Arizona. Founded in 2024 by oncology experts, the company advances a portfolio of innovative cancer therapeutics designed to address critical unmet clinical needs.
Biotechnology
RayThera is a small molecule drug discovery company founded in August 2023, headquartered in San Diego, CA, United States. Its mission is to develop safer, more effective therapeutics by advancing drug discovery with proven expertise and adaptable approaches. The company focuses on transformative therapies for unmet medical needs.
Biotechnology
Turning Point Therapeutics is a clinical-stage precision oncology company based in San Diego, California, that designs and develops targeted cancer therapies. Founded in 2013, the company operates as a subsidiary of Bristol Myers Squibb following its acquisition in 2022.
Biotechnology
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Biotechnology
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Biotechnology
cAMPfield Therapeutics is a biotechnology research company headquartered in San Diego, California. The company focuses on discovering and developing innovative therapeutic treatments targeting specific biological pathways.
Similar biotech company
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Biotechnology
Adcentrx Therapeutics is a privately held biotechnology company founded in 2021 that focuses on accelerating advanced medical treatments. Its research headquarters are located in San Diego, California.
Biotechnology
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Biotechnology
Cold Start Therapeutics is a biopharmaceutical startup headquartered in San Diego, California. The company has raised early-stage funding to advance its therapeutic pipeline.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BlossomHill Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BlossomHill Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →